Premier Functional Medicine
GLP-1s are new medications to many people, but their development has a decades-long history. Learn more about how we got modern GLP-1s.
GLP-1 medications can feel like they arrived out of nowhere, but the science behind them has been unfolding for decades. “GLP-1” stands for glucagon-like peptide-1, a hormone your gut releases after you eat. It helps coordinate blood sugar control and appetite signals—two reasons the GLP-1 drug class has become central to modern weight management.
Here’s the story of when GLP-1 was discovered, how it became a medication, and what researchers still need to learn about long-term use.
Long before GLP-1 itself was discovered, scientists noticed a phenomenon now called the incretin effect: when people consume glucose orally, the body releases more insulin than when the same amount of glucose is delivered intravenously. That suggested the gut was sending hormone signals to the pancreas.
One incretin hormone, GIP (glucose-dependent insulinotropic polypeptide), was identified in the 1970s. But the insulin-boosting effect observed in humans wasn’t fully explained by GIP alone, which kept the search going.
The discovery of GLP-1 wasn’t a single “eureka moment” so much as a rapid series of discoveries in the 1980s. Researchers studying proglucagon (a larger precursor molecule) realized it could be cut into several peptides, including forms of GLP-1. Work in the mid-1980s identified biologically active GLP-1 fragments—especially GLP-1(7-36) amide / GLP-1(7-37)—that had strong insulin-stimulating effects.
By 1986–1987, multiple groups reported that GLP-1 could act as an incretin hormone, stimulating insulin secretion in a glucose-dependent way and lowering blood sugar. Later in 1987, additional human studies reinforced GLP-1’s role as a gut hormone with powerful metabolic effects.
In other words, GLP-1 was “discovered” as a functional incretin hormone in the mid-to-late 1980s, after earlier molecular biology work clarified what proglucagon could produce.
Once GLP-1’s metabolic potential had been discovered, the next challenge was practical: native GLP-1 is broken down quickly in the body, making it difficult to use directly as a drug. Researchers needed longer-acting versions that could survive long enough to be useful.
That led to two key therapeutic strategies:
For weight loss, the star of the show has been GLP-1 receptor agonists.
The early GLP-1 drugs were developed for type 2 diabetes, because the discovery of GLP-1’s ability to improve glucose control was so compelling.
A major milestone came when exenatide (Byetta)—a GLP-1 receptor agonist—became the first GLP-1 agonist approved in the U.S. in April 2005 for type 2 diabetes.
Over time, clinicians also observed consistent weight reduction in many patients using GLP-1 therapies. That observation—paired with new trials designed specifically around obesity—set up the modern weight-loss chapter.
In everyday conversation, “GLP-1” often refers to GLP-1 receptor agonists, but there are several formats and “families” within that idea.
These tend to have stronger effects on gastric emptying (how quickly food leaves the stomach), which can influence post-meal blood sugar. Examples include older options such as exenatide (twice daily) and lixisenatide (diabetes-focused agents).
These are typically dosed daily or weekly and provide steadier receptor activation. Examples include liraglutide (daily) and semaglutide (weekly injection; now also an oral weight-loss form approved in late 2025).
Some newer drugs activate GLP-1 plus another incretin receptor to amplify metabolic effects. The key example is tirzepatide, which targets GIP + GLP-1 and is FDA-approved for chronic weight management.
(Researchers are also studying triple-agonist approaches, but those are still evolving and thus do not have decades of real-world outcomes to back them.)
We’ve discovered that GLP-1 receptor agonists can support weight loss through several overlapping mechanisms:
In many people, the combination of appetite regulation + improved metabolic signaling leads to meaningful, sustained weight loss—especially when paired with nutrition, movement, sleep optimization, and muscle preservation.
GLP-1 medications are not “new” discoveries, but their widespread use for chronic weight management in the wider population is new, and that’s where the long-term questions become important.
What we know clearly from FDA labeling and ongoing monitoring is that there are meaningful risks and precautions, including the following:
The biggest open research and clinical-practice questions tend to be these:
This is why medically supervised prescribing matters: the goal is not only weight loss, but safer weight loss, with the right labs, symptom monitoring, nutrition support, and plan for sustainability.
If you want to discover how GLP-1s can aid your weight loss journey, the best outcomes usually happen when the medication is just one part of a complete strategy—metabolic labs, nutrition planning, strength training to preserve muscle, gut support, sleep and stress optimization, and a personalized maintenance plan. That’s exactly what Premier Functional Medicine in Chandler, AZ, does.
Ready to approach GLP-1s the functional medicine way? Connect with Chandler’s top functional medicine clinic for GLP-1 guidance and a program built around long-term metabolic health.
